Published on Friday September 13, 2013
Smooth Drug Development starts a new bioequivalence trial
Smooth Drug Development starts a new bioequivalence trial of a non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic properties.
The client is a global pharmaceutical and biotechnology organisation, providing affordable, high-quality medicines for a healthier world.
Our clients are leading pharmaceutical, biotech and R&D companies. Our customers are located in Russia, Europe, US and Asia-Pacific region.
Smooth Drug Development, a leading CRO in Russia, CIS and Baltic countries, provides a full range of services for clinical research since 2011.